Hoshi M, Matsuura M, Hayakawa N, Ito C, Kamada N
Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Health Phys. 1996 May;70(5):735-40. doi: 10.1097/00004032-199605000-00017.
The present study presents the Hiroshima University Registry of atomic bomb survivors, of which the total number is about 270,000, and application of absorbed doses. From this registry, we picked up 49,102 survivors and applied organ doses based on the dosimetry system 1986 (DS86), which is named the Atomic Bomb Survivor 1993 Dose (ABS93D). The applied dose data are based on the tables listed in the DS86 final report such as the free-in-air kermas, the house shielding factors, and organ dose factors for the active bone marrow and the breast. Calculations for the 13 other organs provided in DS86 are possible. To obtain the organ doses for each survivor, it is necessary to obtain information concerning (1) place exposed, (2) whether they were shielded or not, and (3) age. ABS93D body transmission factors for active bone marrow for neutrons and gamma rays agreed with DS86 to within a few percent. Of the survivors studied, 35,123 of them were used for the relative risk estimation of leukemia mortality, adopting the same method as the Radiation Effects Research Foundation (RERF) for comparison. For the observation period from 1968 to 1989, the analyzed relative risks for leukemia mortality at 1 Gy by shielded kerma and by active bone marrow dose are 2.01 and 2.37, respectively, which are consistent with the RERF results.
本研究介绍了广岛大学原子弹幸存者登记册,其总数约为270,000人,并介绍了吸收剂量的应用。从该登记册中,我们挑选了49,102名幸存者,并根据1986年剂量测定系统(DS86)应用器官剂量,该剂量被命名为1993年原子弹幸存者剂量(ABS93D)。应用的剂量数据基于DS86最终报告中列出的表格,如空气中自由比释动能、房屋屏蔽因子以及活性骨髓和乳腺的器官剂量因子。DS86中提供的其他13个器官的计算也是可行的。为了获得每个幸存者的器官剂量,有必要获取有关以下方面的信息:(1)暴露地点,(2)是否受到屏蔽,以及(3)年龄。中子和γ射线活性骨髓的ABS93D身体传输因子与DS86的结果相差在百分之几以内。在研究的幸存者中,35,123人被用于白血病死亡率的相对风险估计,采用与辐射效应研究基金会(RERF)相同的方法进行比较。对于1968年至1989年的观察期,屏蔽比释动能和活性骨髓剂量在1 Gy时白血病死亡率的分析相对风险分别为2.01和2.37,这与RERF的结果一致。